• Explore /
  • Poster
  • / BRUIN CLL-314: A phase 3, open-label, randomized study of pirtobrutinib versus ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

BRUIN CLL-314: A phase 3, open-label, randomized study of pirtobrutinib versus ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Abstract Poster

Authors

null

Jennifer Ann Woyach

Ohio State University Comprehensive Cancer Center, Columbus, OH

Jennifer Ann Woyach , Catherine Callaghan Coombs , Katharine L. Lewis , Maricer P. Escalon , Matteo Ceccarelli , Yuanyuan Faith Bian , William G. Wierda

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Chronic Lymphocytic Leukemia (CLL) and Hairy Cell

Clinical Trial Registration Number

NCT05254743

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS7584)

DOI

10.1200/JCO.2023.41.16_suppl.TPS7584

Abstract #

TPS7584

Poster Bd #

132a

Abstract Disclosures

Similar Posters

First Author: George Follows

First Author: Michael Wang

First Author: Ömür Gökmen Sevindik

First Author: Erel Joffe